Novel therapies for Pseudomonas aeruginosa pneumonia

Infectious Disorders - Drug Targets

Volumn 11, Issue 4, 2011, Pages 389-394

  Roux, Damien ^a,b   Ricard, Jean Damien ^a,c  

^a INSERM   (France)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c HÔPITAL LOUIS MOURIER   (France)

Author keywords

Immunotherapy; Nosocomial infection; Type III secretion system; Ventilator associated pneumonia

Indexed keywords

ANTIBIOTIC AGENT; ARENICIN 3; AZITHROMYCIN; BACTERIAL VACCINE; CEFTOBIPROLE; COLISTIN; DORIPENEM; FURANONE DERIVATIVE; KB 001; MACROLIDE; PANOBACUMAB; PLACEBO; POLYPEPTIDE ANTIBIOTIC AGENT; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GENE; BACTERIAL VIRULENCE; BACTERICIDAL ACTIVITY; CANDIDA; GENE EXPRESSION REGULATION; HUMAN; IMMUNOGENICITY; IMMUNOTHERAPY; NEPHROTOXICITY; NONHUMAN; ORAL PARESTHESIA; PATHOPHYSIOLOGY; POLYNEUROPATHY; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS PNEUMONIA; QUORUM SENSING; VISUAL DISORDER;

EID: 79961056767     PISSN: 18715265     EISSN: 18755852     Source Type: Journal    
DOI: 10.2174/187152611796504836     Document Type: Article

References (61)

1. Sadikot, R. T.; Blackwell, T. S.; Christman, J. W.; Prince, A. S. Pathogen-host interactions in Pseudomonas aeruginosa pneumonia. Am. J. Respir. Crit. Care Med., 2005, 171 (11), 1209-23.
2. Diekema, D. J.; Pfaller, M. A.; Jones, R. N.; Doern, G. V.; Winokur, P. L.; Gales, A. C.; Sader, H. S.; Kugler, K.; Beach, M. Survey of bloodstream infections due to gram-negative bacilli: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, and Latin America for the SENTRY Antimicrobial Surveillance Program, 1997. Clin. Infect. Dis., 1999, 29 (3), 595-607.
3. Guidelines for the management of community acquired pneumonia in adults, revised edition. Respirology, 2006, 11 (Suppl 3), S79-s133.
4. Falagas, M. E.; Rafailidis, P. I.; Matthaiou, D. K.; Virtzili, S.; Nikita, D.; Michalopoulos, A. Pandrug-resistant Klebsiella pneumoniae, Pseudomonas aeruginosa and Acinetobacter baumannii infections: characteristics and outcome in a series of 28 patients. Int. J. Antimicrob. Agents, 2008, 32 (5), 450-4.
5. Adamo, R.; Sokol, S.; Soong, G.; Gomez, M. I.; Prince, A. Pseudomonas aeruginosa flagella activate airway epithelial cells through asialoGM1 and toll-like receptor 2 as well as toll-like receptor 5. Am. J. Respir. Cell Mol. Biol., 2004, 30 (5), 627-34.
6. Soong, G.; Reddy, B.; Sokol, S.; Adamo, R.; Prince, A. TLR2 is mobilized into an apical lipid raft receptor complex to signal infection in airway epithelial cells. J. Clin. Invest. 2004, 113 (10), 1482-1489.
7. Drenkard, E.; Ausubel, F. M. Pseudomonas biofilm formation and antibiotic resistance are linked to phenotypic variation. Nature, 2002,416 (6882), 740-743.
8. Mikkelsen, H.; Ball, G.; Giraud, C.; Filloux, A. Expression of Pseudomonas aeruginosa CupD fimbrial genes is antagonistically controlled by RcsB and the EAL-containing PvrR response regulators. PLoS One, 2009, 4 (6), e6018.
9. Smith, R. S.; Iglewski, B. H. Pseudomonas aeruginosa quorum sensing as a potential antimicrobial target. J. Clin. Invest., 2003, 112 (10), 1460-1465.
10. Schuster, M.; Lostroh, C. P.; Ogi, T.; Greenberg, E. P. Identification, timing, and signal specificity of Pseudomonas aeruginosa quorum-controlled genes: a transcriptome analysis. J. Bacteriol., 2003, 185 (7), 2066-2079.
11. Jahoor, A.; Patel, R.; Bryan, A.; Do, C.; Krier, J.; Watters, C.; Wahli, W.; Li, G.; Williams, S. C.; Rumbaugh, K. P. Peroxisome proliferator-activated receptors mediate host cell proinflammatory responses to Pseudomonas aeruginosa autoinducer. J. Bacteriol., 2008,190 (13), 4408-4415.
12. Skindersoe, M. E.; Zeuthen, L. H.; Brix, S.; Fink, L. N.; Lazenby, J.; Whittall, C.; Williams, P.; Diggle, S. P.; Froekiaer, H.; Cooley, M.; Givskov, M. Pseudomonas aeruginosa quorum-sensing signal molecules interfere with dendritic cell-induced T-cell proliferation. FEMS Immunol. Med. Microbiol., 2009, 55 (3), 335-345.
13. Ader, F.; Le Berre, R.; Faure, K.; Gosset, P.; Epaulard, O.; Toussaint, B.; Polack, B.; Nowak, E.; Viget, N. B.; Kipnis, E.; Guery, B. P. Alveolar response to Pseudomonas aeruginosa: role of the type III secretion system. Infect. Immun., 2005, 73(7), 4263-4271.
14. Kubori, T.; Matsushima, Y.; Nakamura, D.; Uralil, J.; Lara-Tejero, M.; Sukhan, A.; Galan, J. E.; Aizawa, S. I. Supramolecular structure of the Salmonella typhimurium type III protein secretion system. Science, 1998, 280 (5363), 602-605.
15. Singh, G.; Wu, B.; Baek, M. S.; Camargo, A.; Nguyen, A.; Slusher, N. A.; Srinivasan, R.; Wiener-Kronish, J. P.; Lynch, S. V. Secretion of Pseudomonas aeruginosa type III cytotoxins is dependent on Pseudomonas quinolone signal concentration. Microb. Pathog., 49 (4), 196-203.
16. Galan, J. E.; Collmer, A. Type III secretion machines: bacterial devices for protein delivery into host cells. Science, 1999,284 (5418), 1322-1328.
17. Hauser, A. R. The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat. Rev. Microbiol., 2009, 7 (9), 654-665.
18. Goure, J.; Pastor, A.; Faudry, E.; Chabert, J.; Dessen, A.; Attree, I. The V antigen of Pseudomonas aeruginosa is required for assembly of the functional PopB/PopD translocation pore in host cell membranes. Infect. Immun, 2004, 72 (8), 4741-4750.
19. Sato, H.; Frank, D. W. ExoU is a potent intracellular phospholipase. Mol. Microbiol, 2004, 53 (5), 1279-1290.
20. Jia, J.; Wang, Y.; Zhou, L.; Jin, S. Expression of Pseudomonas aeruginosa toxin ExoS effectively induces apoptosis in host cells. Infect. Immun 2006, 74 (12), 6557-6570.
21. Shafikhani, S. H.; Morales, C.; Engel, J. The Pseudomonas aeruginosa type III secreted toxin ExoT is necessary and sufficient to induce apoptosis in epithelial cells. Cell Microbiol., 2008, 10 (4), 994-1007.
22. Hauser, A. R.; Cobb, E.; Bodi, M.; Mariscal, D.; Valles, J.; Engel, J. N.; Rello, J. Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit. Care Med., 2002, 30 (3), 521-528.
23. Doring, G.; Pier, G. B. Vaccines and immunotherapy against Pseudomonas aeruginosa. Vaccine, 2008, 26 (8), 1011-1024.
24. Lynch, S. V.; Flanagan, J. L.; Sawa, T.; Fang, A.; Baek, M. S.; Rubio-Mills, A.; Ajayi, T.; Yanagihara, K.; Hirakata, Y.; Kohno, S.; Misset, B.; Nguyen, J. C.; Wiener-Kronish, J. P. Polymorphisms in the Pseudomonas aeruginosa type III secretion protein, PcrV implications for anti-PcrV immunotherapy. Microb. Pathog., 48 (6), 197-204.
25. Sawa, T.; Yahr, T. L.; Ohara, M.; Kurahashi, K.; Gropper, M. A.; Wiener-Kronish, J. P.; Frank, D. W. Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat. Med., 1999, 5 (4), 392-398.
26. Shime, N.; Sawa, T.; Fujimoto, J.; Faure, K.; Allmond, L. R.; Karaca, T.; Swanson, B. L.; Spack, E. G.; Wiener-Kronish, J. P. Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa. J. Immunol., 2001, 167 (10), 5880-5886.
27. Chastre, J.; Dugard, A.; Luyt, C. E.; Wolff, M.; Diehl, J. L.; Jaber, S.; Papazian, L.; Forel, J. M.; Perrotin, D.; Garot, D.; Guery, B.; Kipnis, E.; Mebazaa, A.; Laisné, M. J.; Misset, B.; Philippart, F.; Pearce, T. L. S.; Ploy, M. C.; Andremont, A.; Francois, B. A Pilot Study of the HumaneeredTM anti-PcrV monoclonal antibody, KB001, in Mechanically-Ventilated (MV) Subjects Colonized with Pseudomonas aeruginosa. Am. J. Respir. Crit. Care Med., 2010, 181, A2274.
28. Horn, M. P.; Zuercher, A. W.; Imboden, M. A.; Rudolf, M. P.; Lazar, H.; Wu, H.; Hoiby, N.; Fas, S. C.; Lang, A. B. Preclinical in vitro and in vivo characterization of the fully human monoclonal IgM antibody KBPA101 specific for Pseudomonas aeruginosa serotype IATS-O11. Antimicrob. Agents Chemother., 54 (6), 2338-2344.
29. Lazar, H.; Horn, M. P.; Zuercher, A. W.; Imboden, M. A.; Durrer, P.; Seiberling, M.; Pokorny, R.; Hammer, C.; Lang, A. B. Pharmacokinetics and safety profile of the human antiPseudomonas aeruginosa serotype O11 immunoglobulin M monoclonal antibody KBPA-101 in healthy volunteers. Antimicrob. Agents Chemother., 2009, 53 (8), 3442-3446.
30. Njoroge, J.; Sperandio, V. Jamming bacterial communication: new approaches for the treatment of infectious diseases. EMBO Mol. Med., 2009, 1 (4), 201-210.
31. Hentzer, M.; Wu, H.; Andersen, J. B.; Riedel, K.; Rasmussen, T. B.; Bagge, N.; Kumar, N.; Schembri, M. A.; Song, Z.; Kristoffersen, P.; Manefield, M.; Costerton, J. W.; Molin, S.; Eberl, L.; Steinberg, P.; Kjelleberg, S.; Hoiby, N.; Givskov, M. Attenuation of Pseudomonas aeruginosa virulence by quorum sensing inhibitors. EMBO J., 2003, 22 (15), 3803-3815.
32. Wu, H.; Song, Z.; Hentzer, M.; Andersen, J. B.; Molin, S.; Givskov, M.; Hoiby, N. Synthetic furanones inhibit quorumsensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice. J. Antimicrob. Chemother., 2004,53 (6), 1054-1061.
33. Clatworthy, A. E.; Pierson, E.; Hung, D. T. Targeting virulence: a new paradigm for antimicrobial therapy. Nat. Chem. Biol., 2007, 3 (9), 541-548.
34. Muh, U.; Hare, B. J.; Duerkop, B. A.; Schuster, M.; Hanzelka, B. L.; Heim, R.; Olson, E. R.; Greenberg, E. P. A structurally unrelated mimic of a Pseudomonas aeruginosa acyl-homoserine lactone quorum-sensing signal. Proc. Natl. Acad. Sci. USA, 2006, 103 (45), 16948-16952.
35. Wozniak, D. J.; Keyser, R. Effects of subinhibitory concentrations of macrolide antibiotics on Pseudomonas aeruginosa. Chest, 2004, 125 (2 Suppl), 62S-69S; quiz 69S.
36. Kikuchi, Y.; Tateda, K.; Fuse, E. T.; Matsumoto, T.; Gotoh, N.; Fukushima, J.; Takizawa, H.; Nagase, T.; Standiford, T. J.; Yamaguchi, K. Hyperoxia exaggerates bacterial dissemination and lethality in Pseudomonas aeruginosa pneumonia. Pulm. Pharmacol. Ther., 2009, 22 (4), 333-339.
37. Kohler, T.; Perron, G. G.; Buckling, A.; van Delden, C. Quorum sensing inhibition selects for virulence and cooperation in Pseudomonas aeruginosa. PLoS Pathog., 6 (5), e1000883.
38. Van Delden, C.; Kohler, T.; Francois, B.; Carlet, J. Azitromycin as a Quorum-Sensing Inhibitor for the Prevention of Pseudomonas aeruginosa Ventilator-Associated-Pneumonia, ICAAC2010, Boston.
39. Feola, D. J.; Garvy, B. A.; Cory, T. J.; Birket, S. E.; Hoy, H.; Hayes, D. Jr.; Murphy, B. S. Azithromycin alters macrophage phenotype and pulmonary compartmentalization during lung infection with Pseudomonas. Antimicrob. Agents Chemother., 2010,54 (6), 2437-247.
40. Tsai, W. C.; Rodriguez, M. L.; Young, K. S.; Deng, J. C.; Thannickal, V. J.; Tateda, K.; Hershenson, M. B.; Standiford, T. J. Azithromycin blocks neutrophil recruitment in Pseudomonas endobronchial infection. Am. J. Respir. Crit. Care Med., 2004, 170 (12), 1331-1339.
41. Tamaoki, J.; Kadota, J.; Takizawa, H. Clinical implications of the immunomodulatory effects of macrolides. Am. J. Med., 2004, 117 (Suppl 9A), 5S-11S.
42. Amsden, G. W. Anti-inflammatory effects of macrolides--an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother., 2005, 55 (1), 10-21.
43. Page, M. G.; Heim, J. Prospects for the next anti-Pseudomonas drug. Curr. Opin. Pharmacol., 2009, 9 (5), 558-565.
44. Srinivas, N.; Jetter, P.; Ueberbacher, B. J.; Werneburg, M.; Zerbe, K.; Steinmann, J.; Van der Meijden, B.; Bernardini, F.; Lederer, A.; Dias, R. L.; Misson, P. E.; Henze, H.; Zumbrunn, J.; Gombert, F. O.; Obrecht, D.; Hunziker, P.; Schauer, S.; Ziegler, U.; Kach, A.; Eberl, L.; Riedel, K.; DeMarco, S. J.; Robinson, J. A. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science, 327 (5968), 1010-1013.
45. Desmard, M.; Davidge, K. S.; Bouvet, O.; Morin, D.; Roux, D.; Foresti, R.; Ricard, J. D.; Denamur, E.; Poole, R. K.; Montravers, P.; Motterlini, R.; Boczkowski, J. A carbon monoxide-releasing molecule(CORM-3) exerts bactericidal activity against Pseudomonas aeruginosa and improves survival in an animal model of bacteraemia. FASEB J., 2009, 23 (4), 1023-1031.
46. Linden, P. K.; Paterson, D. L. Parenteral and inhaled colistin for treatment of ventilator-associated pneumonia. Clin. Infect. Dis., 2006,43 (Suppl 2), S89-94.
47. Matthaiou, D. K.; Michalopoulos, A.; Rafailidis, P. I.; Karageorgopoulos, D. E.; Papaioannou, V.; Ntani, G.; Samonis, G.; Falagas, M. E. Risk factors associated with the isolation of colistinresistant gram-negative bacteria: a matched case-control study. Crit. Care Med., 2008, 36 (3), 807-811.
48. Chastre, J.; Wunderink, R.; Prokocimer, P.; Lee, M.; Kaniga, K.; Friedland, I. Efficacy and safety of intravenous infusion of doripenem versus imipenem in ventilator-associated pneumonia: a multicenter, randomized study. Crit. Care Med., 2008, 36 (4), 1089-196.
49. Walkty, A.; Decorby, M.; Nichol, K.; Karlowsky, J. A.; Hoban, D. J.; Zhanel, G. G. In vitro activity of ceftobiprole against clinical isolates of Pseudomonas aeruginosa obtained from Canadian intensive care unit (ICU) patients as part of the CAN-ICU Study. J. Antimicrob. Chemother., 2008, 62 (1), 206-208.
50. Queenan, A. M.; Shang, W.; Bush, K.; Flamm, R. K. Differential selection of single-step AmpC or efflux mutants of Pseudomonas aeruginosa by using cefepime, ceftazidime, or ceftobiprole. Antimicrob. Agents Chemother., 54 (10), 4092-4097.
51. Mushtaq, S.; Warner, M.; Livermore, D. M. In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters. J. Antimicrob. Chemother., 2010, 65(11), 2376-2381
52. Livermore, D. M.; Mushtaq, S.; Warner, M. Activity of BAL30376 (monobactam BAL19764 + BAL29880 + clavulanate) versus Gram-negative bacteria with characterized resistance mechanisms. J. Antimicrob. Chemother., 2010, 65(11),2382-2395.
53. Luyt, C. E.; Clavel, M.; Guntupalli, K.; Johannigman, J.; Kennedy, J. I.; Wood, C.; Corkery, K.; Gribben, D.; Chastre, J. Pharmacokinetics and lung delivery of PDDS-aerosolized amikacin (NKTR-061) in intubated and mechanically ventilated patients with nosocomial pneumonia. Crit. Care, 2009, 13 (6), R200.
54. Kwa, A. L.; Loh, C.; Low, J. G.; Kurup, A.; Tam, V. H. Nebulized colistin in the treatment of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa. Clin. Infect. Dis., 2005, 41 (5), 754-757.
55. Luyt, C. E.; Combes, A.; Nieszkowska, A.; Trouillet, J. L.; Chastre, J. Aerosolized antibiotics to treat ventilator-associated pneumonia. Curr. Opin. Infect. Dis., 2009, 22 (2), 154-158.
56. Meersseman, W.; Lagrou, K.; Spriet, I.; Maertens, J.; Verbeken, E.; Peetermans, W. E.; Van Wijngaerden, E. Significance of the isolation of Candida species from airway samples in critically ill patients: a prospective, autopsy study. Intensive Care Med., 2009, 35 (9), 1526-1531.
57. Ricard, J. D.; Roux, D. Candida pneumonia in the ICU: myth or reality? Intensive Care Med., 2009, 35 (9), 1500-1502.
58. Azoulay, E.; Timsit, J. F.; Tafflet, M.; de Lassence, A.; Darmon, M.; Zahar, J. R.; Adrie, C.; Garrouste-Orgeas, M.; Cohen, Y.; Mourvillier, B.; Schlemmer, B. Candida colonization of the respiratory tract and subsequent Pseudomonas ventilator-associated pneumonia. Chest, 2006, 129 (1), 110-117.
59. Roux, D.; Gaudry, S.; Dreyfuss, D.; El-Benna, J.; de Prost, N.; Denamur, E.; Saumon, G.; Ricard, J. D. Candida albicans impairs macrophage function and facilitates Pseudomonas aeruginosa pneumonia in rat. Crit. Care Med., 2009, 37 (3), 1062-1067.
60. Nseir, S.; Jozefowicz, E.; Cavestri, B.; Sendid, B.; Di Pompeo, C.; Dewavrin, F.; Favory, R.; Roussel-Delvallez, M.; Durocher, A. Impact of antifungal treatment on Candida-Pseudomonas interaction: a preliminary retrospective case-control study. Intensive. Care Med., 2007, 33 (1), 137-142.
61. Roux, D.; Khoy-Ear, L.; Gaudry, S.; Bex, J.; Denamur, E.; Dreyfuss, D.; Ricard, J. D. Antifungal treatment prevents bacterial pneumonia during airway fungal colonization. Am. J. Respir. Crit. Care Med., 2010, 181, A3245.